(Q84340924)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

1 reference

Benjamin Wizel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Josefine Persson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Karolina Thörn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Eszter Nagy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ali M Harandi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

4361-4368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

Herpes Simplex: Insights on Pathogenesis and Possible Vaccines

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Novel approaches in fighting herpes simplex virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Characterization of the antimicrobial peptide derived from sapecin B, an antibacterial protein of Sarcophaga peregrina (flesh fly).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Protective immunity against HSV-2 in the mouse vagina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Immunologic uniqueness of the genital tract: challenge for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Skin scratching switches immune responses from Th2 to Th1 type in epicutaneously immunized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Rabies vaccines: WHO position paper—Recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.02.019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22682292%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference